Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News STEADYMED Ltd STDY

Healthcare Drug Manufacturers - Specialty & Generic
"SteadyMed Ltd is a specialty pharmaceutical company. It has operations in Israel and United States which include research and development, marketing and business development."

Recent & Breaking News (NDAQ:STDY)

SteadyMed Provides Corporate Update and Reports Second Quarter 2016 Financial Results

GlobeNewswire August 15, 2016

SteadyMed Raises up to $32 Million in Private Placement

GlobeNewswire July 29, 2016

SteadyMed to Present at the 2016 JMP Securities Life Sciences Conference

GlobeNewswire June 21, 2016

UPDATE -- SteadyMed and the Pulmonary Hypertension Association Launch Campaign to Highlight Unique and Inspirational Faces Behind PH

GlobeNewswire June 17, 2016

SteadyMed and the Pulmonary Hypertension Association Launch Campaign to Highlight Unique and Inspirational Faces Behind PH

GlobeNewswire June 16, 2016

SteadyMed Provides Corporate Update and Reports First Quarter 2016 Financial Results

GlobeNewswire May 11, 2016

SteadyMed Announces Public Availability of PTAB Decision to Institute Inter Partes Review Proceedings

GlobeNewswire April 25, 2016

SteadyMed to Host an Analyst and Investor Reception

GlobeNewswire April 14, 2016

SteadyMed Announces Initiation of Inter Partes Review Proceedings by U.S. Patent and Trademark Office Against a United Therapeutics Patent

GlobeNewswire April 11, 2016

SteadyMed Provides Corporate Update and Reports Fourth Quarter and Full Year 2015 Financial Results

GlobeNewswire March 29, 2016

SteadyMed to Present at RBC Capital Markets 2016 Global Healthcare Conference

GlobeNewswire February 17, 2016

SteadyMed to Present at 18th Annual BIO CEO & Investor Conference

GlobeNewswire February 2, 2016

SteadyMed Receives Orphan Drug Designation for Trevyent for the Treatment of Pulmonary Arterial Hypertension

GlobeNewswire January 5, 2016

SteadyMed Demonstrates Potential for Reduced Infusion Site Sensitivity Associated With Trevyent Compared to Remodulin

GlobeNewswire December 7, 2015

SteadyMed Reports Recent Developments and Third Quarter 2015 Financial Results

GlobeNewswire November 12, 2015

SteadyMed to Report Recent Developments and Third Quarter 2015 Financial Results

GlobeNewswire November 5, 2015

SteadyMed Announces Positive Clinical Study Results in Support of SMT-201 for the Treatment of Post Surgical Pain in the Home Setting

GlobeNewswire October 28, 2015

SteadyMed Files Inter Partes Review to Invalidate United Therapeutics Patent

GlobeNewswire October 21, 2015

SteadyMed to Participate in Upcoming Investor Conferences

GlobeNewswire September 2, 2015

SteadyMed Provides Insights on Recent Corporate Developments and Reports Second Quarter 2015 Financial Results

GlobeNewswire August 13, 2015